Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Files An 8-K Other Events

Item8.01

On June29, 2017, the Company issued the press release attached
hereto as Exhibit 99.1.

The filing of the attached press release is not an admission as
to the materiality of any information therein. The information
contained in the press release is summary information that is
intended to be considered in the context of more complete
information included in the Companys filings with the U.S.
Securities and Exchange Commission, or the SEC, and other public
announcements that the Company has made and may make from time to
time by press release or otherwise. The Company undertakes no
duty or obligation to update or revise the information contained
in this report, although it may do so from time to time as its
management believes is appropriate. Any such updating may be made
through the filing of other reports or documents with the SEC,
through press releases or through other public disclosures. For
important information about forward looking statements, see the
Safe Harbor section of the press release in Exhibit 99.1 attached
hereto.

(d) Exhibits.

PROTEOSTASIS THERAPEUTICS, INC. Exhibit
EX-99.1 2 d418978dex991.htm EX-99.1 EX-99.1 Exhibit 99.1     Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis Screening Initiated in Phase 2 Portion of PTI-428 Study,…
To view the full exhibit click here
About Proteostasis Therapeutics, Inc. (NASDAQ:PTI)

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.